Current Report Filing (8-k)
14 Avril 2015 - 10:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 9, 2015
Portola Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-35935 |
|
20-0216859 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
|
|
|
270 E. Grand Avenue
South San Francisco, California |
|
94080 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants telephone number, including area code: (650) 246-7300
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the
following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On April 9, 2015 Nicholas Galakatos, a member of the Board of Directors of Portola
Pharmaceuticals, Inc. (the Company), informed the Company that he does not intend to stand for reelection at the Companys 2015 annual meeting of stockholders. He advised the Board that his decision was not related to any
disagreement with the Companys operations, policies, or practices. Dr. Galakatos will continue to serve as director and member of the Audit and Compensation Committees until the Companys 2015 Annual Meeting of Stockholders.
Dr. Galakatos joined the Board in 2003, and the Company thanks Dr. Galakatos for over eleven years of service in successfully guiding the Company
through multiple important phases in its history.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Portola Pharmaceuticals, Inc. |
|
|
|
|
Dated: April 14, 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By: |
|
/s/ Mardi C. Dier |
|
|
|
|
|
|
Mardi C. Dier |
|
|
|
|
|
|
Executive Vice President and Chief Financial Officer |
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Portola Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur Portola Pharmaceuticals Inc